Purple Biotech Ltd.

As of June 30, 2026, Purple Biotech Ltd. carries a market capitalization of 1.84B, placing it among publicly traded companies globally. Its enterprise value stands at 57.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Purple Biotech Ltd. has 1.86B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Purple Biotech Ltd. maintains a current ratio of 3.70, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.10, indicating moderate leverage, while an interest coverage ratio of -413.47 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Purple Biotech Ltd. posted a negative return on equity (ROE) of -110.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -100.91, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 9.75, a quick read on workforce productivity versus industry peers.

As of the close on October 20, 2026, Purple Biotech Ltd.'s stock has declined approximately 9.09% over the past 52 weeks. The 50-day moving average sits at 1.00, while the 200-day moving average is 1.45.

Over the twelve months ended June 30, 2026, Purple Biotech Ltd. generated - - in revenue and converted that into -7.26B in net income, yielding earnings per share of -3.98. EBITDA reached -8.33B, while operating income came in at -2.34B.

As of June 30, 2026, Purple Biotech Ltd. holds 1.81B in cash and equivalents against 39.72M in total debt, resulting in a net debt position of -1.55B. Total book value stands at 3.64B, with working capital of 1.42B providing operational flexibility.

Purple Biotech Ltd. produced -2.30B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Purple Biotech Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -126.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -127.24, meaning Purple Biotech Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Purple Biotech Ltd.'s most recent stock split took place on January 6, 2019 with a 20:1 split ratio.

As of June 30, 2026, Purple Biotech Ltd. has an Altman Z-Score of -36.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.